Latest news with #Agilon
Globe and Mail
6 days ago
- Business
- Globe and Mail
agilon health, inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
The DJS Law Group announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President, CEO, and Board Director Steven Sell stepped down from his positions. The Company added, 'In a separate press release, the Company today also issued its second quarter 2025 earnings results. As part of that announcement, and in conjunction with this leadership transition, the Company is withdrawing its previous full year 2025 earnings guidance.' Based on this news, shares of Agilon fell more than 27% in after hours trading following the Company's release. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
6 days ago
- Business
- Business Wire
agilon health, inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President, CEO, and Board Director Steven Sell stepped down from his positions. The Company added, 'In a separate press release, the Company today also issued its second quarter 2025 earnings results. As part of that announcement, and in conjunction with this leadership transition, the Company is withdrawing its previous full year 2025 earnings guidance.' Based on this news, shares of Agilon fell more than 27% in after hours trading following the Company's release. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Globe and Mail
7 days ago
- Business
- Globe and Mail
AGL Investors Have Opportunity to Join agilon health, inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President and CEO Steven Sell was stepping down immediately. The Company also withdrew its full-year 2025 financial guidance. Based on this news, shares of Agilon fell by more than 27.2% in after hours trading on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
7 days ago
- Business
- Business Wire
AGL Investors Have Opportunity to Join agilon health, inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President and CEO Steven Sell was stepping down immediately. The Company also withdrew its full-year 2025 financial guidance. Based on this news, shares of Agilon fell by more than 27.2% in after hours trading on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
7 days ago
- Business
- Yahoo
Agilon Health (AGL) Reports Q2 Loss, Misses Revenue Estimates
Agilon Health (AGL) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -127.27%. A quarter ago, it was expected that this senior-focused health care company would post a loss of $0.01 per share when it actually produced break-even earnings, delivering a surprise of +100%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Agilon, which belongs to the Zacks Medical Services industry, posted revenues of $1.39 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.98%. This compares to year-ago revenues of $1.48 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Agilon shares have lost about 10.5% since the beginning of the year versus the S&P 500's gain of 6.1%. What's Next for Agilon? While Agilon has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Agilon was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $1.46 billion in revenues for the coming quarter and -$0.28 on $5.95 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Progyny (PGNY), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This provider of fertility and family building benefits is expected to post quarterly earnings of $0.44 per share in its upcoming report, which represents a year-over-year change of +2.3%. The consensus EPS estimate for the quarter has been revised 4.1% lower over the last 30 days to the current level. Progyny's revenues are expected to be $322.5 million, up 6.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilon Health, Inc. (AGL) : Free Stock Analysis Report Progyny, Inc. (PGNY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
